Search results
Results from the WOW.Com Content Network
CORRECTION: (Oct. 24, 2024, 3:34 p.m. ET) Because of an editing error, a previous version of this article misstated the recommended dose for the pneumonia vaccine. It is intended as a single dose ...
The ACIP recommends people 65 and older get the pneumococcal vaccine to prevent respiratory infections if they’ve either never received it or don’t know if they have. Pneumococcal disease ...
Causes of pneumonia in the elderly. Pneumonia can be caused by a buildup of bacteria, viruses, or fungi in the lungs. There are several types of bacteria that can cause pneumonia, some typical and ...
The polysaccharide vaccines, while effective in healthy adults, are not effective in children less than two years old or those with poor immune function. [1] [4] These vaccines are generally safe. [1] With the conjugate vaccine about 10% of babies develop redness at the site of injection, fever, or change in sleep. [1] Severe allergies are very ...
A pulmonary shunt often occurs when the alveoli fill with fluid, causing parts of the lung to be unventilated although they are still perfused. [2] Intrapulmonary shunting is the main cause of hypoxemia (inadequate blood oxygen) in pulmonary edema and conditions such as pneumonia in which the lungs become consolidated. [2]
Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...
The disease can lead to infections in several parts of the body including the lungs, where they can cause pneumonia. There are around 100 different strains of the bacteria that can cause those ...
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).